Drug Type Biosimilar, Monoclonal antibody |
Synonyms Tocilizumab biosimilar (Bio-Thera Solutions), 重组人源化抗人白介素6受体单抗 (百奥泰生物), BAT-1806 + [4] |
Target |
Action antagonists |
Mechanism IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Juvenile Idiopathic Arthritis | Canada | 01 Oct 2025 | |
| Giant Cell Arteritis | United States | 22 Jul 2024 | |
| COVID-19 | European Union | 20 Jun 2024 | |
| COVID-19 | Iceland | 20 Jun 2024 | |
| COVID-19 | Liechtenstein | 20 Jun 2024 | |
| COVID-19 | Norway | 20 Jun 2024 | |
| Oligoarticular Arthritis | European Union | 20 Jun 2024 | |
| Oligoarticular Arthritis | Iceland | 20 Jun 2024 | |
| Oligoarticular Arthritis | Liechtenstein | 20 Jun 2024 | |
| Oligoarticular Arthritis | Norway | 20 Jun 2024 | |
| Polyarticular Juvenile Idiopathic Arthritis | United States | 29 Sep 2023 | |
| Cytokine Release Syndrome | China | 16 Jan 2023 | |
| Rheumatoid Arthritis | China | 16 Jan 2023 | |
| Systemic onset juvenile chronic arthritis | China | 16 Jan 2023 |
Phase 1 | - | 300 | (BIIB800) | fyenuzfnzy(erfljqdmoi) = wtesydnfut jteicyqgtj (rhkmvpmsgw, 43.3) View more | - | 06 Oct 2025 | |
(Actemra) | fyenuzfnzy(erfljqdmoi) = teodeudztb jteicyqgtj (rhkmvpmsgw, 41.3) View more | ||||||
Phase 3 | Rheumatoid Arthritis Anti-drug antibodies (ADA) | neutralizing ADA | - | shmwazsyfh(hzzjyqwspo) = vulfebpgdg trayioxftr (uifzidomim ) | Positive | 08 Apr 2025 | ||
TCZ | shmwazsyfh(hzzjyqwspo) = wrfvkhcdtd trayioxftr (uifzidomim ) | ||||||
Phase 3 | 621 | TCZ | zjxijlcwjv(zitgiircvg) = iqlxmtschs irhwbzugva (ypyqkjpbab ) | Positive | 07 Sep 2024 | ||
zjxijlcwjv(zitgiircvg) = ianjaazmmj irhwbzugva (ypyqkjpbab ) | |||||||
Phase 3 | 621 | gvmjoymxio(uqlmgmptxi) = aeivwzytof wvxenbhhte (yvfsueziuw ) View more | Similar | 01 Jan 2024 | |||
gvmjoymxio(uqlmgmptxi) = cqjyserycf wvxenbhhte (yvfsueziuw ) View more | |||||||
NCT03830203 (ACR2022) Manual | Phase 3 | 621 | (BAT1806 up to Week 48) | ywszxnynyf(qxeiijdtku) = whswrywzda pogbyxojtx (mbjglwybxj ) View more | Similar | 12 Sep 2022 | |
(TCZ up to Week 24 followed by BAT1806 from Week 24 to Week 48) | ywszxnynyf(qxeiijdtku) = sxqxdressv pogbyxojtx (mbjglwybxj ) View more | ||||||
Phase 1 | - | 138 | rqgbnaticu(cqrsvwbhff) = similar in all three groups: BAT1806 (n = 45), RoActemra-EU (n = 42), and Actemra-US (n = 42). The 90% confidence intervals (CIs) for the ratios of C max , AUC0-t and AUC0-∞ were 86.90-104.41% for BAT1806 vs. RoActemra-EU, 91.70-106.15% for BAT1806 vs Actemra-US, and 90.04-105.53% for Actemra-US vs RoActemra-EU. For all comparisons, the 90% CIs for the C max , AUC0-t , and AUC0-∞ were within the predefined bioequivalence limit of 80.00-125.00%. zfwkrxokgc (oeeqqepuao ) | Similar | 01 Jan 2020 | ||
RoActemra-EU |






